Department of Neurosurgery, Haseki Training and Research Hospital, Istanbul, Turkey.
Acta Neurochir (Wien). 2010 Dec;152(12):2161-6. doi: 10.1007/s00701-010-0775-6. Epub 2010 Aug 28.
Cerebral vasospasm is the common cause of poor outcome after aneurysmal subarachnoid hemorrhage (aSAH). Although many agents are experimentally and clinicaly used to protect or recover from vasospasm, an effective neurotherapeutic drug is still missing. Erythropoietin (EPO) is recently a promising candidate. The aim of this study is to investigate the dose-dependent effects of recombinant human EPO (rhEPO) on arterial wall in a rat femoral artery vasospasm model.
Thirty two animals were divided into four groups: vasospasm without any treatment (group A), vasospasm +250 IU/kg rhEPO group (group B), vasospasm +500 IU/kg rhEPO group (group C), and control group (group D). Rat femoral artery vasospasm model was used. For groups B and C, 7 days of 250 IU/kg and 500 IU/kg intraperitoneal rhEPO in 0.3 ml saline were administered respectively; and for groups A and D, 0.3 ml saline were administered intraperitoneally without any treatment. After 7 days, histological and morphometric analyses were carried out.
Vasospasm alone group demonstrated the highest vessel wall thicknesses, comparing to other groups (p < 0.001). While for groups B and C, vessel wall thickness values were significantly higher than the control group (p < 0.001), between these two groups, there was no significant difference achieved (p > 0.05).
In our study, there was no significant difference between the two rhEPO treatment groups, but rhEPO treatment was shown to be histologically and morphometrically effective in vasospasm. However, if dosage of EPO treatment is augmented, successful results may be achieved.
脑血管痉挛是动脉瘤性蛛网膜下腔出血(aSAH)后预后不良的常见原因。尽管许多药物已在实验和临床中用于预防或治疗血管痉挛,但仍缺乏有效的神经治疗药物。促红细胞生成素(EPO)最近成为一个有前景的候选药物。本研究的目的是在大鼠股动脉血管痉挛模型中研究重组人促红细胞生成素(rhEPO)对动脉壁的剂量依赖性影响。
32只动物分为四组:未治疗的血管痉挛组(A组)、血管痉挛+250 IU/kg rhEPO组(B组)、血管痉挛+500 IU/kg rhEPO组(C组)和对照组(D组)。采用大鼠股动脉血管痉挛模型。B组和C组分别腹腔注射0.3 ml生理盐水溶解的250 IU/kg和500 IU/kg rhEPO,连续7天;A组和D组腹腔注射0.3 ml生理盐水,不做任何处理。7天后,进行组织学和形态学分析。
与其他组相比,单纯血管痉挛组的血管壁厚度最高(p < 0.001)。B组和C组的血管壁厚度值显著高于对照组(p < 0.001),但这两组之间无显著差异(p > 0.05)。
在我们的研究中,两个rhEPO治疗组之间没有显著差异,但rhEPO治疗在组织学和形态学上对血管痉挛有效。然而,如果增加EPO治疗的剂量,可能会取得成功的结果。